The estimated Net Worth of James E Dentzer is at least 1.98 百万$ dollars as of 27 January 2022. Mr. Dentzer owns over 5,500 units of Curis Inc stock worth over 330,873$ and over the last 17 years he sold CRIS stock worth over 92,443$. In addition, he makes 1,557,770$ as President、 Chief Executive Officer、 Director at Curis Inc.
Sign up
Mr. Dentzer CRIS stock SEC Form 4 insiders trading
James has made over 4 trades of the Curis Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,500 units of CRIS stock worth 17,160$ on 27 January 2022.
The largest trade he's ever made was selling 6,752 units of Curis Inc stock on 23 January 2020 worth over 11,276$. On average, James trades about 564 units every 27 days since 2007. As of 27 January 2022 he still owns at least 64,877 units of Curis Inc stock.
You can see the complete history of Mr. Dentzer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Dentzer biography
James E. Dentzer serves as President, Chief Executive Officer, Director of the Company. Mr. Dentzer served as our Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as our Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer since March 2016. Previously, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., an RNA interference-based biopharmaceutical company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a commercial-stage medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc., a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc., a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical company, in the U.S. and Asia. Mr. Dentzer holds a B.A. in philosophy from Boston College and an M.B.A. from the University of Chicago.
What is the salary of James Dentzer?
As the President、 Chief Executive Officer、 Director of Curis Inc, the total compensation of James Dentzer at Curis Inc is 1,557,770$. There are no executives at Curis Inc getting paid more.
How old is James Dentzer?
James Dentzer is 53, he's been the President、 Chief Executive Officer、 Director of Curis Inc since 2018. There are 8 older and 2 younger executives at Curis Inc. The oldest executive at Curis Inc is Martyn Greenacre, 78, who is the Independent Chairman of the Board.
What's James Dentzer's mailing address?
James's mailing address filed with the SEC is 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON, MA, 02421.
Insiders trading at Curis Inc
Over the last 24 years, insiders at Curis Inc have traded over 10,321,234$ worth of Curis Inc stock and bought 10,678,594 units worth 25,596,192$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Discovery Technologies Ltd ...、James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of 811,553$. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth 17,160$.
What does Curis Inc do?
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
What does Curis Inc's logo look like?
Complete history of Mr. Dentzer stock trades at Amicus Therapeutics Inc、Curis Inc、Dicerna Pharmaceuticals Inc
Curis Inc executives and stock owners
Curis Inc executives and other stock owners filed with the SEC include:
-
James Dentzer,
President, Chief Executive Officer, Director -
James E. Dentzer,
Pres, CEO & Director -
Robert Martell,
Head - Research and Development -
William Steinkrauss,
Chief Financial Officer -
Dr. Robert E. Martell,
Head of R&D -
William E. Steinkrauss,
Chief Financial Officer -
Martyn Greenacre,
Independent Chairman of the Board -
Kenneth Kaitin,
Independent Director -
Marc Rubin,
Independent Director -
Lori Kunkel,
Independent Director -
Elif McDonald,
VP of Investor Relations & Corp. Communications -
Dr. Reinhard Wilhelm von Roemeling,
Sr. VP of Clinical Devel. -
Mark W. Noel,
VP of Technology Management & Intellectual Property -
John Hohneker,
Director -
James R Mcnab,
Director -
David Tuck,
Chief Medical Officer -
Ali Ph.D. Fattaey,
President & COO -
Kenneth Pienta,
Director -
Discovery Technologies Ltd ...,
-
Douglas Melton,
Director -
Lee L Rubin,
Senior Vice President,Research -
Mary Elizabeth Potthoff,
Vice President,General Counsel -
Mani Mohindru,
Sr. VP, Corp. Strategy & IR -
Christopher U Missling,
Sr. Vice President, Finance -
Ruth B Kunath,
Director -
Jaye Viner,
Chief Medical Officer -
Michael Gray,
Chief Financial Officer -
James R Tobin,
Director -
Mark Noel,
Vice President, Tech. Manage. -
Maurizio Voi,
Chief Medical Officer -
Joseph Md Phd Davie,
Director -
Susan B Bayh,
Director -
Changgeng Qian,
VP, Research & Preclinical Dev -
Capital Management, Llcra C...,
-
Partners L P/Ilbiotechnolog...,
-
Stephen Carter,
Director -
Mitchell Keegan,
Vice-President -
Joseph M Davie,
Director -
Daniel R Passeri,
President and CEO -
Anne Elizabeth Borgman,
Director -
Diantha Duvall,
CFO -
Jonathan B. Zung,
CDO